Name | Roquefort Therapeutics |
---|---|
Epic | ROQ |
Isin | GB00BMDQ2T15 |
Industry | Open End and Miscellaneous Investment Vehicles |
Latest share price | 3.93p | Net gearing | n/a |
---|---|---|---|
Market capitalisation | £5.34 | Debt ratio | n/a |
Shares in issue | 129.15 | Debt-to-equity ratio | n/a |
P/E ratio | n/a | Assets / equity ratio | n/a |
Total dividends per share | n/a | Price to book value | n/a |
Dividend yield | n/a | ROCE | -76.19 |
Dividend cover | n/a | EPS growth | n/a |
Earning per share | -1.56 | 52-week high / low | 3.35p / 9.25p |
Type | Ex-date | Pay-date | Net-dividend |
---|---|---|---|
No dividends declared |
Company name | Roquefort Therapeutics |
---|---|
Address | Eccleston Yards, 25 Eccleston Place, London, United Kingdom, SW1W 9NF |
Telephone | +44 (0)20 3290 9339 |
Website | http://www.roquefortinvest.com/ |
Director | Position |
---|---|
Mr Dr Darrin Disley | Non-Executive Director |
Dr Simon Sinclair | Non-Executive Director |
Ms Jean Duvall | Non-Executive Director |
Mr Stephen Paul West | Executive Chairman |
Mr Trevor Ajanthan (Ajan) Reginald | Chief Executive Officer |
Dr Michael Stein | Independent Non-Executive Director |
Mr Professor Sir Martin Evans | Chief Scientific Officer |
Assets £ (m) | 2022 | 2021 |
---|---|---|
Reporting date | 31/12/22 | 31/12/21 |
Intangible asssets and goodwill | 5.34 | 1.48 |
Investments and other non-current assets | n/a | n/a |
Total non-current assets | 5.34 | 1.48 |
Inventory / work in progress | n/a | n/a |
Trade and other receivables | 0.1 | 2.18 |
Cash and equivalents | 2.32 | 0.9 |
Other current assets and asset held for resale | n/a | n/a |
Total of all assets | 7.77 | 4.56 |
Liabilities £ (m) | 2022 | 2021 |
---|---|---|
Short term liabilities | 0.28 | 0.2 |
Long term liabilities | 0.28 | 0.28 |
Other liabilites / pension etc | n/a | n/a |
Total of all liabilities | 0.56 | 0.48 |
Net assets £ (m) | 2022 | 2021 |
---|---|---|
Net assets | 7.21 | 4.08 |
Equity £ (m) | 2022 | 2021 |
---|---|---|
Share capital | 1.29 | 0.72 |
Minority interests | n/a | n/a |
Retained earnings | -2.55 | -0.91 |
Share premium account | 4.4 | 3.46 |
Total equity | 7.21 | 4.08 |
Income £ (m) | 2022 | 2021 |
---|---|---|
Turnover | n/a | n/a |
Operating profit | -1.63 | -0.92 |
Pre-tax profit | -1.63 | -0.92 |